Clinical Trials Logo

Advanced Malignancies clinical trials

View clinical trials related to Advanced Malignancies.

Filter by:

NCT ID: NCT00948961 Completed - Clinical trials for Advanced Malignancies

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Start date: September 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.

NCT ID: NCT00779428 Completed - Clinical trials for Advanced Malignancies

Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

Start date: July 2006
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to provide treatment to patients who have participated on a prior protocol investigating Tanespimycin (KOS-953,17-AAG)

NCT ID: NCT00741403 Completed - Lymphoma Clinical Trials

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Start date: August 2008
Phase: Phase 1
Study type: Interventional

An open label, dose-escalation study to evaluate safety, tolerability, maximum tolerated dose (MTD), efficacy, and pharmacokinetics (PKs) of CPI-613 given twice weekly for three consecutive weeks in cancer patients The objectives of this study are: - To determine the safety and MTD of CPI-613 when administered 2x weekly for 3 consecutive weeks. - To determine pharmacokinetics of CPI-613 following intravenous (IV) administration. - To observe the anti-tumor effects of CPI-613, if any occur.

NCT ID: NCT00724425 Terminated - Clinical trials for Advanced Malignancies

A Phase 1 Dose Escalation Study of IPI-493

Start date: July 2008
Phase: Phase 1
Study type: Interventional

IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90) and is orally bioavailable via a novel formulation.

NCT ID: NCT00679133 Completed - Clinical trials for Advanced Malignancies

Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies

Start date: April 2008
Phase: Phase 1
Study type: Interventional

In this study, MGCD265, a new anticancer drug under investigation, is given daily on a 7 days on / 7 days off schedule to patients with advanced malignancies to study its safety profile.

NCT ID: NCT00676299 Completed - Pharmacokinetics Clinical Trials

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Start date: August 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess JNJ-26483327 (a drug in development for cancer) for the safety of the drug in patients with advanced solid tumors that have not responded or are no longer responding to available therapies. The absorption, breakdown and elimination of the drug will also be studied.

NCT ID: NCT00652158 Terminated - Clinical trials for Advanced Malignancies

A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies

Start date: April 2006
Phase: Phase 1
Study type: Interventional

This is a phase 1 clinical trial designed to evaluate increasing durations of MLN8054 oral dosing in patients with advanced malignancies. MLN8054 will be given once daily for 4 to 7 consecutive days per week for 2 to 3 weeks. Following the 2- to 3-week treatment period there will be a 2 week recovery period.

NCT ID: NCT00651664 Completed - Clinical trials for Advanced Malignancies

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

Start date: October 22, 2007
Phase: Phase 1
Study type: Interventional

This is a multicenter, dose escalation, phase 1 study of MLN8237 in adult participants with advanced malignancies (excluding those with primary bone marrow involvement, such as leukemias and multiple myeloma).

NCT ID: NCT00611793 Completed - Clinical trials for Advanced Malignancies

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

Start date: October 2004
Phase: Phase 1
Study type: Interventional

PTK787/ZK222584 is an orally active inhibitor of VEGF-R tyrosine kinases. Bevacizumab is an intravenous humanized monoclonal antibody directed against vascular endothelial growth factor. By binding to VEGF, bevacizumab blocks VEGF-A receptor binding. Due to the different mechanisms of action and the non-overlapping toxicity profiles of the two agents, it is hoped that a combination regimen incorporating both compounds will produce increased activity without enhanced toxicity.

NCT ID: NCT00500903 Completed - Clinical trials for Advanced Malignancies

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

Start date: May 15, 2007
Phase: Phase 1
Study type: Interventional

To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of MLN8237 when given by mouth (PO) for a minimum of 7 and a maximum of 21 consecutive days, followed by a 14-day recovery period.